The Bio-Rad D-10 HbA1c analyser is a widely used HPLC instrument across NHS biochemistry laboratories, providing accurate, IFCC-aligned glycated haemoglobin measurement for diabetes diagnosis and monitoring. Whether you are setting up the instrument for the first time, troubleshooting an error, or ensuring your laboratory meets UKAS ISO 15189:2022 accreditation requirements, understanding the D-10 operating principles is essential. This guide covers the key elements of the Bio-Rad D-10 HbA1c manual — from start-up and calibration to result interpretation, maintenance, and MHRA regulatory compliance — in line with current NICE, NHS, and UK safety guidance.

What Is the Bio-Rad D-10 and How Is It Used for HbA1c Testing?

The Bio-Rad D-10 is a benchtop ion-exchange HPLC analyser used in NHS laboratories to quantify HbA1c for type 2 diabetes diagnosis and glycaemic monitoring, with results traceable to the IFCC reference procedure.

Have any more questions about this? Message our pharmaceutical team to get more info →

The Bio-Rad D-10 is a benchtop high-performance liquid chromatography (HPLC) analyser designed for the quantitative determination of haemoglobin A1c (HbA1c) in whole blood samples. It is a laboratory instrument and is not a point-of-care device; samples collected in GP practices and other community settings are typically sent to an accredited clinical laboratory for analysis. The D-10 is widely used across NHS biochemistry and haematology laboratories in the United Kingdom as part of diabetes diagnosis and long-term glycaemic monitoring.

The instrument operates on the principle of ion-exchange HPLC, separating haemoglobin variants based on their ionic interactions with a cation-exchange resin column. As the sample passes through the column under a programmed buffer gradient, different haemoglobin fractions — including HbA1c — elute at characteristic retention times, allowing precise quantification. This method is IFCC-aligned and NGSP-certified; it is not itself an IFCC reference method but is traceable to the IFCC reference measurement procedure and meets the standardisation requirements of the National Glycohaemoglobin Standardisation Programme (NGSP).

In clinical practice, the D-10 is used to:

• Diagnose type 2 diabetes when HbA1c is ≥48 mmol/mol on two separate occasions (or once if classic symptoms of hyperglycaemia are present), in appropriate patient groups (see limitations below)

• Monitor glycaemic control in patients with established type 1 or type 2 diabetes

• Identify non-diabetic hyperglycaemia (HbA1c 42–47 mmol/mol) in individuals undergoing targeted testing, to guide lifestyle intervention

Important limitations — HbA1c should not be used to diagnose diabetes in the following situations:

• Suspected type 1 diabetes (diagnosis should be based on symptoms and plasma glucose)

• Children and young people

• Pregnancy or within two months postpartum

• Acute illness or recent surgery

• Recent blood transfusion or conditions associated with altered red cell turnover (e.g., haemolytic anaemia, iron deficiency anaemia, haemoglobinopathies)

• Advanced chronic kidney disease (CKD)

In these circumstances, fasting plasma glucose (FPG) or an oral glucose tolerance test (OGTT) should be used instead, in line with NICE NG28, NICE NG17, and WHO guidance.

The analyser accepts EDTA whole blood samples; run time is programme-dependent and operators should consult the current Bio-Rad D-10 operator's manual for precise timing. Its compact design makes it suitable for high-throughput hospital biochemistry departments and smaller accredited laboratory settings. Operators must always refer to the current Bio-Rad D-10 operator's manual alongside local standard operating procedures (SOPs) to ensure consistent, safe, and accurate use.

Setting Up the Bio-Rad D-10: Step-by-Step Operating Instructions

Start-up requires system self-diagnostics, column priming, QC verification before patient runs, and adequate EDTA sample mixing; operators must follow the current Bio-Rad D-10 operator's manual and local SOPs throughout.

Before operating the Bio-Rad D-10, ensure the instrument has been positioned on a stable, level surface away from direct sunlight and sources of vibration. Allow the analyser to reach room temperature (18–32°C) if it has been stored in a cooler environment. Confirm that all reagent packs — including the D-10 Dual Kit buffers and the separation column — are within their stated expiry dates and have been equilibrated to room temperature for at least 30 minutes prior to use.

1. Step-by-step start-up procedure:
2. Power on the instrument and allow the system to complete its self-diagnostic initialisation sequence.
3. Install or confirm the correct column is seated and that buffer lines are free from air bubbles.
4. Prime the system using the instrument's built-in priming function to purge lines and stabilise the column.
5. Run quality control (QC) materials before processing patient samples. Calibration is not required at every run; it should be performed when starting a new reagent kit lot, following column replacement, or when QC results fall outside acceptable limits — refer to the operator's manual and local SOP for specific criteria.
6. Enter or confirm calibration data as prompted by the on-screen interface when calibration is indicated.
7. Prepare EDTA whole blood samples: invert tubes adequately (typically 8–10 times) to ensure thorough mixing and check for clots before loading. Refer to the operator's manual and product insert for acceptable primary tube types, sample cup requirements, and minimum volume specifications, as these are programme- and accessory-dependent.
8. Place samples into the sample tray, ensuring tubes are correctly capped.
9. Select the appropriate programme (e.g., HbA1c mode) and initiate the run sequence.

During operation, the instrument automatically aspirates, dilutes, and injects each sample. Results are displayed on-screen and can be printed or exported to a laboratory information management system (LIMS). At the end of each session, operators should perform the system wash cycle as described in the manual to prevent column contamination and maintain analytical integrity. Never leave the instrument idle with buffers unconnected, as this may introduce air into the fluidic system.

Calibration, Quality Control, and UKAS Compliance Guidance

Calibration uses IFCC-traceable two-level calibrators and is required at new kit lot, column change, or QC failure; daily QC assessed by Westgard rules and UK NEQAS participation are mandatory for ISO 15189:2022 accreditation.

Accurate HbA1c measurement depends on rigorous calibration and quality control (QC) practices. The Bio-Rad D-10 uses a two-level calibration system, with calibrators traceable to the IFCC reference measurement procedure. Calibration should be performed when starting a new reagent kit lot, following column replacement, and whenever QC results fall outside acceptable limits. Calibration data are entered via the instrument interface, and the system calculates a response factor used to adjust subsequent patient results.

Quality control materials — typically supplied as low and high HbA1c controls — must be run at a minimum of once per day of patient testing, or more frequently in line with local laboratory policy, risk assessment, or following maintenance or troubleshooting activities. Results should be plotted on a Levey-Jennings chart and assessed using Westgard rules to identify systematic bias or imprecision. Any QC failure must be investigated and documented before patient results are authorised.

For laboratories seeking or maintaining UKAS accreditation (United Kingdom Accreditation Service) under ISO 15189:2022, the following are essential:

• Documented SOPs for calibration, QC, and corrective action

• Participation in an approved External Quality Assurance (EQA) scheme — UK NEQAS for HbA1c is the recognised provider for this measurand in the UK

• Traceability of all calibrators and reagents to recognised reference standards (IFCC/NGSP)

• Regular review of uncertainty of measurement (in line with UKAS guidance document M3003) and method verification data

The D-10 is NGSP-certified and IFCC-aligned, supporting its use in NICE-aligned clinical pathways. Laboratories should retain all calibration and QC records for the minimum period specified by their accreditation body and local governance policies.

Interpreting HbA1c Results in Line with NICE and NHS Standards

Results are reported in mmol/mol; ≥48 mmol/mol confirms type 2 diabetes (with repeat), 42–47 mmol/mol indicates non-diabetic hyperglycaemia, and haemoglobin variants or interfering conditions require cautious interpretation.

HbA1c results from the Bio-Rad D-10 are reported in mmol/mol (IFCC units), in accordance with current NHS and NICE guidance. The older percentage (NGSP/DCCT) units are no longer used routinely in UK clinical practice, though some legacy documentation may still reference them. Clinicians and laboratory staff should be familiar with both formats to avoid misinterpretation.

NICE-aligned HbA1c thresholds (NICE NG28, NICE NG17, NHS/WHO diagnostic guidance):

• Below 42 mmol/mol: Normal — diabetes unlikely

• 42–47 mmol/mol: Non-diabetic hyperglycaemia — intensive lifestyle intervention recommended; refer to the NHS Diabetes Prevention Programme (NDPP) where eligible

• 48 mmol/mol or above: Diagnostic of type 2 diabetes in appropriate patient groups (requires confirmation on a second sample unless symptomatic hyperglycaemia is present)

Treatment targets should be individualised in discussion with the patient. Per NICE NG28:

• 48 mmol/mol is the target for adults with type 2 diabetes managed by lifestyle modification alone or with a single glucose-lowering agent that does not carry a risk of hypoglycaemia

• 53 mmol/mol is the target when a drug associated with hypoglycaemia risk (e.g., a sulfonylurea or insulin) is used

• Targets should be relaxed further for individuals at high risk of hypoglycaemia, those with frailty, limited life expectancy, or significant comorbidities — always individualise

HbA1c should not be used to diagnose diabetes in the groups listed in the first section of this article (see above). In those situations, FPG or OGTT should be used.

Certain conditions can interfere with HbA1c accuracy, including haemoglobin variants (e.g., HbS, HbC, HbE), haemolytic anaemia, iron deficiency anaemia, and recent blood transfusion. The D-10 HPLC method can detect many haemoglobin variants through characteristic chromatographic patterns, and the instrument flags suspected variant samples; however, not all variants are resolved or detected by this method, and interference is method-dependent. When atypical chromatograms are identified, results should be interpreted with caution, specialist haematology or variant analysis advice sought, and alternative markers — such as fructosamine or glycated albumin — considered.

Healthcare professionals should always interpret HbA1c results in the full clinical context, including patient symptoms, concurrent medications (e.g., corticosteroids, SGLT2 inhibitors), and individual risk factors. Patients should be informed of their results in plain language and supported with appropriate education and follow-up.

Troubleshooting Common Errors and Maintenance Procedures

Pressure errors, aspiration failures, and QC failures are the most common issues; daily wash cycles, weekly probe cleaning, and monthly column performance review form the core maintenance schedule.

The Bio-Rad D-10 is a robust instrument, but operators may encounter a range of errors during routine use. Understanding common fault codes and their causes enables prompt resolution and minimises downtime.

Common errors and likely causes:

• Pressure errors (high or low): Often caused by a blocked or degraded separation column, air in the fluidic lines, or a failing pump. Check buffer connections, prime the system, and inspect the column for signs of deterioration.

• Sample aspiration failures: May result from insufficient sample volume, incorrectly seated tubes, or a blocked sample probe. Ensure minimum sample volumes are met (refer to the operator's manual) and clean the probe as directed.

• QC out-of-range results: Investigate reagent expiry, incorrect storage of controls, calibration drift, or column ageing. Recalibrate if indicated and repeat QC before releasing patient results.

• Haemoglobin variant flags: The instrument may display alerts when unusual chromatographic peaks are detected. Do not suppress these flags without clinical review; refer atypical chromatograms for specialist interpretation.

Routine maintenance schedule:

• Daily: System wash cycle at end of session; inspect waste container levels

• Weekly: Clean the sample probe and surrounding area; check buffer levels

• Monthly: Review column performance metrics (peak resolution, retention times); inspect tubing for wear; document retention time stability

• As required: Column replacement — the timing should be guided by manufacturer recommendations in the operator's manual and by performance indicators such as increasing back-pressure, deteriorating peak resolution, shifting retention times, or adverse QC trends, rather than a fixed injection count alone

Operators should perform carryover checks and verify retention time stability following any maintenance activity or column change, and document findings accordingly.

All maintenance activities should be documented in the instrument log, including the date, action taken, and operator identity. Preventive maintenance contracts with Bio-Rad or an approved service engineer are recommended for annual servicing. Never attempt internal repairs without appropriate training, as this may void the warranty and compromise analytical performance.

Safe Handling, Waste Disposal, and MHRA Regulatory Considerations

Whole blood samples are Category B biological substances requiring PPE and P650 packaging compliance; sodium azide waste must not enter metal pipework, and serious device incidents must be reported to the MHRA via Yellow Card.

All staff operating the Bio-Rad D-10 must be trained in safe handling of biological samples. Whole blood specimens are classified as Category B biological substances (UN3373) under UK transport and laboratory safety regulations; packaging and transport must comply with P650 packaging instructions. Personal protective equipment (PPE) — including gloves, a laboratory coat, and eye protection — must be worn at all times when handling samples, reagents, and waste materials.

Reagents used with the D-10, including buffers and wash solutions, may contain sodium azide or other preservatives that are hazardous in concentrated form. A specific hazard of sodium azide is its reaction with copper or lead plumbing to form explosive metal azides; it must not be disposed of directly down metal-containing drains. Operators must consult the relevant Safety Data Sheets (SDS), available from Bio-Rad, before use, and follow HSE COSHH guidance for all hazardous substances. Reagents must be stored at the temperatures specified in the product insert and kept away from incompatible substances.

Waste disposal guidance:

• Liquid biological waste (including used samples and contaminated buffers) must be decontaminated using an approved disinfectant or autoclaved before disposal, in line with local infection control policy and HTM 07-01 (Safe Management of Healthcare Waste)

• Sodium azide-containing waste must be disposed of via an approved hazardous waste contractor in accordance with SDS instructions and local waste management policy — do not dispose of via copper or lead pipework

• Sharps (e.g., sample needles) must be disposed of in a UN-approved sharps container

• Reagent packaging and consumables should be disposed of as clinical or hazardous waste as appropriate

From a regulatory standpoint, the Bio-Rad D-10 is classified as an in vitro diagnostic medical device (IVD) and is subject to oversight under the UK MDR 2002 (as amended) and monitored by the MHRA. The device currently holds CE IVD marking, which continues to be accepted in Great Britain during the UK transitional period; laboratories should monitor MHRA guidance for updates regarding UKCA marking requirements.

Laboratories must ensure the device is used within its intended purpose. Serious incidents — those that have led, or might have led, to death or serious deterioration in a patient's state of health — must be reported to the MHRA via the Yellow Card portal for medical devices. Near-misses and local patient safety incidents should be reported through the local Learning from Patient Safety Events (LFPSE) system. Compliance with these requirements is essential for patient safety and regulatory accountability.

Frequently Asked Questions